Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibit...
Main Authors: | Omar S. Al-Odat, Max von Suskil, Robert J. Chitren, Weam O. Elbezanti, Sandeep K. Srivastava, Tulin Budak-Alpddogan, Subash C. Jonnalagadda, Bharat B. Aggarwal, Manoj Pandey |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.699629/full |
Similar Items
-
Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01) -
Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Frontiers Production Office
Published: (2021-08-01) -
Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy
by: Hoda Sobhy Ibrahim, et al.
Published: (2019-12-01) -
AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
by: David J. Mallick, et al.
Published: (2020-08-01) -
Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
by: Anne Slomp, et al.
Published: (2018-11-01)